HKEX Announcement Highlights | GUOXIA TECH to List Tomorrow with 1,890.73x Oversubscription; Big Three Airlines Report Over 10% YoY Passenger Traffic Growth in November

Stock News
12/15

【New Listings】 GUOXIA TECH (02655): Hong Kong public offering oversubscribed by 1,890.73 times, with an issue price of HK$20.1 per share. EasyHealth (02661) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23. Hanshi Aite-B (03378) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23. Nobikan (02635) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23.

【Major Developments】 CMOC (03993) plans to acquire three major gold mining assets in Brazil for US$1.015 billion. CNGR (02579) H-shares included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists. Botai Auto (02889) secures first project nomination from a leading domestic NEV customer. Concornew Energy (00182) to sell 100% equity in Cangzhou Julong for RMB65.3 million. FOSUN PHARMA (02196) subsidiary to invest RMB1.412 billion for a controlling stake in Green Valley Pharma. UQ Holdings (02177) to acquire Japanese pharmacy chain Akahige for JPY2.701 billion.

【Financial Data】 MCC (01618) reports new contract value of RMB958.13 billion for Jan-Nov, down 8.6% YoY. New China Life (01336) records RMB188.85 billion in premium income for Jan-Nov, up 16% YoY. China Southern Airlines (01055) sees November passenger traffic rise 10.42% YoY. China Shenhua (01088) coal sales volume at 389.5 million tonnes for Jan-Nov, down 7.7% YoY. China Eastern Airlines (00670) reports 10.35% YoY growth in November passenger traffic. Air China (00753) passenger traffic up 10.1% YoY in November.

【Buybacks & Share Purchases】 TENCENT (00700) repurchases 1.051 million shares for HK$636 million on Dec 15. Xiaomi (01810) buys back 7.2 million shares for HK$302 million on Dec 15. Geely Auto (00175) repurchases 1.991 million shares for HK$34.75 million on Dec 15. Kuaishou-W (01024) acquires 462,000 shares for HK$29.93 million on Dec 15. RemeGen (09995) plans buyback worth RMB20-40 million. Everest Medicines (01952) receives over HK$38 million in share purchases from directors and major shareholders.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10